Illumina, Inc. (ILMN) Holdings Raised by Starfire Investment Advisers Inc.

Share on StockTwits

Starfire Investment Advisers Inc. boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 69.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,950 shares of the life sciences company’s stock after acquiring an additional 800 shares during the period. Starfire Investment Advisers Inc.’s holdings in Illumina were worth $605,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Massmutual Trust Co. FSB ADV grew its holdings in shares of Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares in the last quarter. Financial Advocates Investment Management boosted its stake in Illumina by 1,430.0% during the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after buying an additional 572 shares during the period. Proficio Capital Partners LLC boosted its stake in Illumina by 61.7% during the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after buying an additional 37 shares during the period. Lake Point Wealth Management purchased a new position in Illumina during the fourth quarter worth $30,000. Finally, Moody National Bank Trust Division purchased a new position in Illumina during the fourth quarter worth $31,000. Institutional investors own 90.46% of the company’s stock.

In other news, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $280.11, for a total transaction of $34,733.64. Following the sale, the senior vice president now owns 6,879 shares in the company, valued at $1,926,876.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, January 23rd. The stock was sold at an average price of $303.53, for a total value of $1,001,649.00. Following the sale, the director now owns 329,979 shares in the company, valued at approximately $100,158,525.87. The disclosure for this sale can be found here. Insiders sold 34,826 shares of company stock valued at $10,604,560 over the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

Several research analysts have commented on ILMN shares. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $347.00 price objective for the company in a research note on Friday, January 11th. Bank of America reaffirmed a “buy” rating and set a $355.00 price objective on shares of Illumina in a research note on Wednesday, January 30th. Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective for the company. in a research note on Friday, January 25th. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Morgan Stanley dropped their price objective on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research note on Monday, January 7th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $346.97.

Shares of ILMN stock traded up $0.34 on Friday, hitting $319.03. The stock had a trading volume of 1,107,619 shares, compared to its average volume of 963,822. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.49 and a quick ratio of 2.27. The company has a market capitalization of $46.87 billion, a P/E ratio of 55.77, a PEG ratio of 2.39 and a beta of 1.17. Illumina, Inc. has a one year low of $226.62 and a one year high of $372.61.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The firm had revenue of $867.00 million during the quarter, compared to the consensus estimate of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.44 earnings per share. On average, analysts anticipate that Illumina, Inc. will post 6.53 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Highlight Press and is owned by of Highlight Press. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://highlightpress.com/2019/04/19/illumina-inc-ilmn-holdings-raised-by-starfire-investment-advisers-inc.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: What is channel trading?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.